Frederick H. Rein

Frederick H. Rein

Frederick H. Rein

Fred Rein, a partner in Goodwin’s IP Litigation Group, is a U.S. registered patent attorney with 25 years of experience in intellectual property law. He has handled patent cases across the life sciences (including biological products, chemical processes, diagnostic kits, enantiomers, new chemical entities, metabolites, methods of treatment, pharmaceutical formulations and polymorphs) and has extensive experience addressing the complex interplay between FDA and patent law. In addition to his litigation practice, Mr. Rein focuses on strategic counseling and patent-related due diligence.

Professional Experience

Prior to joining Goodwin in 2001 to help start its IP law practice in New York, Mr. Rein was a partner at Kenyon & Kenyon, a well-known IP law firm. He also previously served on the Patents Committee of the Association of the Bar of the City of New York.


While in law school, Mr. Rein was Managing Editor of the Boston College Environmental Affairs Law Review. In graduate school, he was a recipient of a New York University Fellowship and a Conoco Scholarship.

Areas of Practice


Mr. Rein has represented:

  • Abic Ltd. in a section 337 action in the U.S. International Trade Commission relating to a process of manufacturing the active ingredient in a generic version of CARDIZEM
  • American Cyanamid in patent litigation relating to an acellular pertussis vaccine
  • General Foods in patent litigation relating to a coffee decaffeination process
  • Geneva Pharmaceuticals as an intervenor in litigation against the FDA invalidating the “successful defense” requirement for 180-day generic exclusivity
  • Geneva Pharmaceuticals in patent litigations relating to generic versions of SELDANE and ZANTAC
  • Impax Laboratories in patent litigations relating to generic versions of DITROPAN XL and WELLBUTRIN XL
  • Institut Pasteur in patent litigation in U.S. Bankruptcy Court relating to HIV-1,2 diagnostic kits
  • Teva as an intervenor in litigation against the FDA relating to FDA approval of a product in patent litigation
  • Teva in patent litigations relating to, inter alia, generic versions of CLARITIN, ELOXATIN, LIPITOR, LOVAZA, MONOPRIL, PAXIL, RELAFEN and REBETOL



J.D., 1989
Boston College Law School
M.A., 1986
New York University
B.S., Biology, 1984
Rensselaer Polytechnic Institute


1989 to 1990 U.S. District Court for the Central District of California, Honorable Ralph J. Geffen



New York
U.S. Patent and Trademark Office (USPTO)


U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers